Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: loteprednol etabonate

« Back to Dashboard
Loteprednol etabonate is the generic ingredient in three branded drugs marketed by Bausch And Lomb Inc, Bausch And Lomb, and Pharmos, and is included in six NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has ten patent family members in nine countries.

There are nine drug master file entries for loteprednol etabonate. Three suppliers are listed for this compound.

Summary for Generic Name: loteprednol etabonate

Tradenames:3
Patents:1
Applicants:3
NDAs:6
Drug Master File Entries: see list9
Suppliers: see list3
Therapeutic Class:Ophthalmic Agents

Pharmacology for Ingredient: loteprednol etabonate

Clinical Trials for: loteprednol etabonate

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Status: Completed Condition: Dry Eye

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Status: Completed Condition: Allergic Conjunctivitis

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Status: Completed Condition: Inflammation; Pain; Cataract

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Status: Completed Condition: Ocular Inflammation

Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
Status: Completed Condition: Inflammation; Pain

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Status: Completed Condition: Conjunctivitis

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Completed Condition: Allergic Conjunctivitis

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Status: Active, not recruiting Condition: Dry Eyes

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998RXYes<disabled><disabled>
Bausch And Lomb Inc
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC202872-001Sep 28, 2012RXYes5,800,807<disabled>Y<disabled>
Bausch And Lomb
LOTEMAX
loteprednol etabonate
OINTMENT;OPHTHALMIC200738-001Apr 15, 2011RXYes<disabled><disabled>
Pharmos
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020841-001Mar 9, 1998DISCNNo<disabled><disabled>
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: loteprednol etabonate

Country Document Number Publication Date
Germany69817788Aug 05, 2004
Brazil9807117Apr 25, 2000
Australia6253398Aug 18, 1998
Germany69817788Oct 09, 2003
Canada2278802Dec 24, 2002
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc